fnarena2 時間
ResMed: Another Positive Quarterly Surprise?
UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...
Listed drug development sector has several promising stories to tell this year
It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...
Future Market Insights6 時間
Sleep Apnea Devices Market to Reach USD 20.4 Billion by 2033 at a 9.5% of CAGR, Amid Rising ...
The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...
Anti-snoring Devices Market to Hit USD 1.45 Billion by 2029 with 9.8% CAGR | MarketsandMarkets
The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ 0.91 ...
Anti-snoring Devices Market to Hit USD 1.45 Billion by 2029 with 9.8% CAGR ...
The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ ...
Le Lézard5 日
Anti-snoring Devices Market to Hit USD 1.45 Billion by 2029 with 9.8% CAGR ...
The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ 0.91 billion in 2024 and an impressive US$ 1.45 billion by 2029 ...